Sumitomo Pharma Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNPUF research report →
Price Chart
About the company
Sumitomo Pharma Co. , Ltd. is a global enterprise specializing in the manufacturing and distribution of a diverse portfolio of products, including pharmaceuticals, food ingredients and additives, chemical product materials, and veterinary medicines.
- CEO
- Toru Kimura
- IPO
- 2012
- Employees
- 3,123
- HQ
- Osaka, OS, JP
Get TickerSpark's AI analysis on DNPUF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.77B
- P/E
- 5.02
- Fwd P/E
- 0.04
- PEG
- 0.01
- P/S
- 1.33
- P/B
- 1.50
- EV/EBITDA
- 5.42
- Div Yield
- 0.00%
- Gross Margin
- 54.99%
- Op Margin
- 10.05%
- Net Margin
- 23.73%
- ROE
- 35.89%
- ROIC
- 7.64%
Latest fiscal year · YoY change
- Revenue
- $456.15B+14.4%
- Gross Profit
- $258.51B+5.3%
- Op Income
- $50.66B
- Net Income
- $107.54B+355.0%
- EPS
- $270.03+353.9%
- OCF Growth
- +337.4%
- FCF Growth
- +1846.1%
- 52W High
- $19.20
- 52W Low
- $8.41
- 50D MA
- $8.86
- 200D MA
- $12.14
- Beta
- 0.45
- RSI (14)
- 15
- Avg Volume
- 61
No earnings-call transcripts are available for DNPUF yet.
- Free Float
- 47.0%
- Shares Outstanding
- 448.59M
- Float Shares
- 210.70M
Our DNPUF coverage
Recent articles, reports, and earnings notes.
No research on DNPUF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DNPUF report →Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
businesswire.com · Jun 10
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
seekingalpha.com · Feb 20
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
cnbc.com · Feb 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.